CorMedix Inc. (CRMD) Short Interest Down 10.2% in December

CorMedix Inc. (NYSEAMERICAN:CRMD) saw a large decrease in short interest in December. As of December 29th, there was short interest totalling 4,000,834 shares, a decrease of 10.2% from the December 15th total of 4,456,413 shares. Currently, 6.4% of the company’s stock are sold short. Based on an average daily trading volume, of 1,626,878 shares, the short-interest ratio is presently 2.5 days.

In other news, CEO Khoso Baluch acquired 104,166 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were acquired at an average cost of $0.48 per share, with a total value of $49,999.68. Following the completion of the acquisition, the chief executive officer now owns 225,373 shares of the company’s stock, valued at $108,179.04. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Steven W. Lefkowitz acquired 135,416 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average cost of $0.48 per share, for a total transaction of $64,999.68. The disclosure for this purchase can be found here. Insiders have purchased a total of 312,498 shares of company stock worth $149,999 over the last ninety days.

Hedge funds have recently modified their holdings of the business. Elliott Management Corp boosted its position in CorMedix by 177.8% during the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock worth $1,785,000 after purchasing an additional 2,666,668 shares in the last quarter. Susquehanna International Group LLP boosted its position in CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock worth $886,000 after purchasing an additional 2,085,670 shares in the last quarter. Sabby Management LLC purchased a new position in CorMedix during the second quarter worth approximately $1,818,000. Finally, Vanguard Group Inc. boosted its position in CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock worth $518,000 after purchasing an additional 35,148 shares in the last quarter.

Several analysts recently commented on the company. Zacks Investment Research lowered CorMedix from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price (up from $3.00) on shares of CorMedix in a report on Monday, September 25th.

CorMedix (CRMD) opened at $0.53 on Thursday. The stock has a market capitalization of $36.99, a P/E ratio of -0.87 and a beta of 0.52. CorMedix has a 1 year low of $0.32 and a 1 year high of $2.48.

WARNING: “CorMedix Inc. (CRMD) Short Interest Down 10.2% in December” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://sportsperspectives.com/2018/01/11/cormedix-inc-crmd-short-interest-down-10-2-in-december.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply